276 related articles for article (PubMed ID: 26933914)
1. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
2.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
3. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
5. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
[TBL] [Abstract][Full Text] [Related]
6. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
8. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
9. [Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers].
Lyu X; Huang J; Liu J; Wang W; Su Y; Zhang W; Sun Y; Ying J; Wang J; Sun Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):346-50. PubMed ID: 25030589
[TBL] [Abstract][Full Text] [Related]
10. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Resetkova E; Wang H; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Hamilton SR; Albarracin CT
Clin Cancer Res; 2006 Aug; 12(15):4598-604. PubMed ID: 16899607
[TBL] [Abstract][Full Text] [Related]
11. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract][Full Text] [Related]
12. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Catenacci DV; Tesfaye A; Tejani M; Cheung E; Eisenberg P; Scott AJ; Eng C; Hnatyszyn J; Marina N; Powers J; Wainberg Z
Future Oncol; 2019 Jun; 15(18):2073-2082. PubMed ID: 31094225
[TBL] [Abstract][Full Text] [Related]
13. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
17. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
18. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
[TBL] [Abstract][Full Text] [Related]
19. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
20. CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances.
Huang L; Xu AM; Peng Q
Int J Clin Exp Pathol; 2015; 8(2):1929-37. PubMed ID: 25973085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
